Neurizon significantly advances NUZ-001, enters global licensing agreement

Neurizon Therapeutics (ASX:NUZ) has this week arrived at its next “watershed moment” as it looks to become a leader in neurodegenerative disease treatments, executing a global license agreement with Elanco Animal Health Inc.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The deal will see Elanco and its affiliates share Monepantel, the active pharmaceutical ingredient in Neurizon’s flagship therapy, NUZ-001, moving forward.

“There’s no two ways about it – this Elanco licensing deal is a watershed moment for this company,” Neurizon CEO Dr Michael Thurn told HotCopper in a Watchlist interview. “It’s all about speed, to regulatory approval, to market, but also speed to making NUZ-001 available to people who have few options.”

NUZ has been up around +5% over the last month before this new deal.

Join the discussion: See what HotCopper users are saying about Actinogen Medical Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.